Skip to main content

Pediatrix Medical Group Inc

For the period ended Dec 31, 2023. Filed Feb 20, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 20, 2024

MD$31.49+0.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pediatrix Medical Group, Inc.
Date:February 20, 2024By:/s/ James D. Swift, M.D.
James D. Swift, M.D.
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ James D. Swift, M.D.Chief Executive Officer and DirectorFebruary 20, 2024
James D. Swift, M.D.(Principal Executive Officer)
/s/ C. Marc RichardsChief Financial Officer and Executive Vice PresidentFebruary 20, 2024
C. Marc Richards(Principal Financial Officer and Principal Accounting Officer)
/s/ Mark S. OrdanDirector and Chair of the BoardFebruary 20, 2024
Mark S. Ordan
/s/ Guy P. SansoneLead Independent DirectorFebruary 20, 2024
Guy P. Sansone
/s/ Laura A. LinynskyDirectorFebruary 20, 2024
Laura A. Linynsky
/s/ Thomas A. McEachinDirectorFebruary 20, 2024
Thomas A. McEachin
/s/ Michael A. RuckerDirectorFebruary 20, 2024
Michael A. Rucker
/s/ John M. Starcher, Jr.DirectorFebruary 20, 2024
John M. Starcher, Jr.
/s/ Shirley A. WeisDirectorFebruary 20, 2024
Shirley A. Weis
/s/ Sylvia J. YoungDirectorFebruary 20, 2024
Sylvia J. Young
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.